抗菌药物的耐药性：与Wellcome Trust合作，通过拉动激励措施解决研发资源的差距
Not enough new antibiotics are in development to guarantee that we can continue to treat infections. Current market conditions will not incentivise the investment necessary to restock the antibiotic pipeline, and “push” funding that directly supports early-stage R&D is insufficient to create a functioning market for the future.
This briefing outlines why pull incentives are necessary; some of the key principles they need to fulfill; and next steps towards implementing or piloting a pull incentive.
Not enough new antibiotics are in development to guarantee that we can continue to treat infections. Current market conditions will not incentivise the investment necessary to restock the antibiotic pipeline, and “push” funding that directly supports early-stage R&D is insufficient to create a functioning market for the future.
This briefing outlines why pull incentives are necessary; some of the key principles they need to fulfill; and next steps towards implementing or piloting a pull incentive.